Lior Carmon

Visionary
DISC Type : Ds

Co-Founder and CSO at Imyun Pharmaceuticals

Tel Aviv-Yafo, Tel Aviv District, Israel

Overview

Lior is an immunologist and biopharma executive with over 25 years of experience translating scientific innovation into commercial success. He is the owner of Biopharma Investment and Management, a consultancy and CRO focused on immunology. A serial entrepreneur, he has co-founded multiple biotech companies, including Imyun and BIoKine Therapeutics. People who have worked with him describe him as creative, innovative, and enthusiastic.

Lior demonstrates a deep intellectual curiosity for the mechanisms behind complex diseases, often sharing and commenting on new research in neuroinflammation, oncology, and immune system function. His focus is on bridging the gap between scientific discovery and real-world application, driven by a passion for advancing therapeutic concepts into clinical development.

Unique fact: He co-founded BIoKine Therapeutics after completing his PhD in immunology at the prestigious Weizmann Institute of Science.

Personality Overview

Risk Tolerant

Objective Evaluator

Big Vision Person

They are very professional in their approach and can weigh multiple perspectives together.  Reading between the lines and seeing beyond your words comes naturally to them. They might take some time to make their mind up but once they do, they don't change it easily.

Topics They Care About

Immunotherapy Innovation
His career focuses on developing novel immunotherapies, including cancer vaccines and T-cell therapies, through his roles at Imyun Pharmaceuticals, Sakura Bio, and VaxilBio.
Biopharma Commercialization
As owner of a consultancy, he specializes in translating scientific concepts into commercially viable products through fundraising, strategic partnerships, and asset scouting.
Neuroinflammation Research
He shows a strong interest in the intersection of the immune system and neurological diseases, sharing research on Parkinson's, multiple sclerosis, and the Epstein-Barr virus.

Media Appearances

Lior has no verified media appearances

Work History

6-2024
Co-Founder and CSO at Imyun Pharmaceuticals
10-2022 - 2-2026
Director at Sakura Bio
4-2022 - 6-2025
Director at Protica Bio
6-2019 - 11-2025
VP Innovation at VLX Ventures
1-2019 - 4-2025
Expert Manager at Catenion

Education

1995 - 1999
PhD from Weizmann Institute of Science
2006 - 2006
Executive Studies for CEOs from University of California, Irvine - The Paul Merage School of Business

More Information

Social Presence :

Prographics :

Exp : 26 Location : Tel Aviv-Yafo, Tel Aviv District, Israel Job Level : Leadership Designation : Co-Founder and CSO at Imyun Pharmaceuticals
URL has been copied!

Insights For Selling To Lior

During A Call Or A Meeting

DO's

  • Use phrases like 'your team deserves', 'best in class' etc.
  • Suggest clear next steps with confidence, don't be vague or hesitant
  • Let them know of potential risks but suggest mitigation methods alongside

DONT's

  • Don't take their patience for granted, avoid long-winding sermons
  • Avoid putting conscious effort into relationship-building
  • Don't go over them unless you are left with no other option

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Lior is

  • Strong proof of impact and their conviction will matter the most, but they wouldn't want to act unilaterally either
  • Will you ever get a clear answer from Lior

  • They will say no if they are not convinced but you will have to prompt them.

Insights For Deal Planning

    How fast (or slow) will Lior move?

  • They will want to understand things well but can move fast once they have a clear picture.
  • Can Lior take some risk or not?

  • They have good risk tolerance but are likely to think it through once or twice.

You And Lior

Personality Compatibility


More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.